Review
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Surg. Feb 27, 2021; 13(2): 96-115
Published online Feb 27, 2021. doi: 10.4240/wjgs.v13.i2.96
Research progress on O-GlcNAcylation in the occurrence, development, and treatment of colorectal cancer
Fang-Xing Peng, Yao Liu
Yao Liu, Fang-Xing Peng, Department of Gastrointestinal Surgery, The Second Affiliated Hospital of North Sichuan Medical College, Mianyang 621000, Sichuan Province, China
Yao Liu, Fang-Xing Peng, Department of Gastrointestinal Surgery, Sichuan Mianyang 404 Hospital, Mianyang 621000, Sichuan Province, China
Author contributions: Liu Y and Peng FX contributed equally to this work; Peng FX conceptualized the research study; Liu Y wrote the manuscript; All authors have read and approved the final manuscript.
Conflict-of-interest statement: The authors report no conflicts of interest in this work.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Fang-Xing Peng, MD, Chief Doctor, Department of Gastrointestinal Surgery, The Second Affiliated Hospital of North Sichuan Medical College, Sichuan Mianyang 404 Hospital, No. 56 Yuejin Road, Fucheng District, Mianyang 621000, Sichuan Province, China. pfx120@126.com
Received: October 17, 2020
Peer-review started: October 17, 2020
First decision: December 1, 2020
Revised: December 21, 2020
Accepted: December 29, 2020
Article in press: December 29, 2020
Published online: February 27, 2021
Processing time: 109 Days and 22.3 Hours
Abstract

For a long time, colorectal cancer (CRC) has been ranked among the top cancer-related mortality rates, threatening human health. As a significant post-translational modification, O-GlcNAcylation plays an essential role in complex life activities. Related studies have found that the occurrence, development, and metastasis of CRC are all related to abnormal O-GlcNAcylation and participate in many critical biological processes, such as gene transcription, signal transduction, cell growth, and differentiation. Recently, nucleotide sugar analogs, tumor-specific carbohydrate vaccine, SIRT1 longevity gene, dendritic cells as targets, and NOTCH gene have become effective methods to induce antitumor therapy. Not long ago, checkpoint kinase 1 and checkpoint kinase 2 were used as therapeutic targets for CRC, but there are still many problems to be solved. With an in-depth study of protein chip, mass spectrometry, chromatography, and other technologies, O-GlcNAcylation research will accelerate rapidly, which may provide new ideas for the research and development of antitumor drugs and the discovery of new CRC diagnostic markers.

Keywords: Colorectal cancer; O-GlcNAcylation; Antitumor therapy; CHK1 and CHK2; Chip; Diagnostic markers

Core Tip: This article mainly reviews the occurrence and development of O-GlcNAcylation in colorectal cancer and the corresponding therapeutic targets. After a thorough review of the literature, we analyze and summarize O-GlcNAcylation research and predict that investigations will accelerate rapidly, which may provide new ideas for the development of antitumor drugs and promote the discovery of new colorectal cancer diagnostic markers.